Alloy vs FuturHealth
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alloy
Best for women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directoryStarting at $80/mo
FuturHealth
Best for readers who want both brand-name and compounded GLP-1 options on one platform with registered-dietitian nutrition coaching, AND are willing to read the data-breach litigation disclosure before signing upStarting at $199/mo
Side-by-Side Comparison
| Feature | Alloy | FuturHealth |
|---|---|---|
| Overall Score | ✓7.4/10 | 6.7/10 |
| Starting Price | ✓$80/mo | $199/mo |
| Editorial Rating | ✓3.7 ★ /5 | 3.4 ★ /5 |
| Features | 8 features | 8 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Alloy
Pros
- ✓Broadest GLP-1 formulary in our catalog: brand Wegovy + brand Zepbound + oral Wegovy + compounded semaglutide + compounded tirzepatide + compounded liraglutide
- ✓All consulting doctors are certified by The Menopause Society — only ~1,000 such certified practitioners exist among ~20,000 OB-GYNs in the US
- ✓Brand-name Wegovy starting at $199/mo and compounded liraglutide starting at $80/mo cover both ends of the price/access spectrum
- ✓STARTGLP1 promo code knocks $50 off the first month per the public site
Cons
- ✗Not available in Louisiana or Mississippi (verified) — readers in those two states should be routed elsewhere
- ✗Initial consultation is $49 and is separate from medication cost — readers should know there's a non-refundable upfront fee
- ✗Menopause-specialty framing — best fit for women in menopause/perimenopause, not the right product for men or younger women whose primary need is weight loss
FuturHealth
Pros
- ✓LegitScript Certified and HITRUST Certified — two independently verifiable telehealth/health-data trust marks
- ✓Both brand-name (Ozempic, Wegovy, Mounjaro, Zepbound) and clinician-discretionary compounded options on one platform
- ✓Bundled registered-dietitian nutrition guidance — most pure-Rx telehealths leave nutrition support to the patient
Cons
- ✗ACTIVE LITIGATION: Wilson v. FuturHealth Inc., U.S. District Court Southern District of California, Case No. 3:2025cv00157, alleging unauthorized access to G-Plans subscriber data on/before October 16, 2024 and asserting CCPA, medical-confidentiality, and negligence claims. Material disclosure for any reader signing up.
- ✗BBB complaint pattern: multiple consumer reports of recurring unauthorized charges (e.g. $396/month) without medication being received — verify cancellation flow before subscribing
- ✗Pharmacy partners are described as 'licensed, U.S.-based pharmacies' but no specific 503A/503B partners are publicly named
- ✗Pricing is not displayed on the public landing page — visible only after qualification questionnaire/portal login
- ✗Clinical platform is white-labeled on top of SteadyMD and OpenLoop infrastructure — FuturHealth is the front-end brand, not the first-party prescribing entity
Our Verdict
Alloy edges out FuturHealth with a higher overall score of 7.4/10 and is particularly strong for women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory. FuturHealth remains a solid alternative, especially if you're looking for readers who want both brand-name and compounded GLP-1 options on one platform with registered-dietitian nutrition coaching, AND are willing to read the data-breach litigation disclosure before signing up.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.